Proteins at mucosal and cellular surfaces

Proteins at mucosal and cellular surfaces is a broad, descriptive category rather than a specific molecular target. It encompasses a wide variety of proteins found at the interface of mucosal membranes and cell surfaces, including mucins, cell adhesion molecules (CAMs), and various membrane-anchored receptors (Source: PubMed, PMID: 22174442). These proteins play critical roles in maintaining the mucosal barrier, facilitating cell-cell interactions, and mediating immune responses to pathogens (Source: NIH, StatPearls). In pharmacology, this term is often associated with non-specific cytoprotective agents like sucralfate, which binds to various proteins (such as albumin and fibrinogen) exposed at the site of mucosal injury to form a protective barrier (Source: DrugBank, DB00364). While specific proteins within this group, such as Mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) or Mucin-1 (MUC1), are targeted by precise biological therapies like vedolizumab, the collective phrase is too broad to be considered a single canonical therapeutic target (Source: UniProt, Q13477). Consequently, this designation is more useful for describing a physiological location or a general mechanism of action rather than a specific drug-receptor interaction. Drugs targeting these surfaces are primarily used in the treatment of gastrointestinal and inflammatory conditions. The safety profile of such interventions depends heavily on whether the binding is non-specific and localized or targeted and systemic.

Other names

Mucosal surface proteinsCell surface proteinsMembrane-associated proteinsMucosal barrier proteins

Drugs interacting with this broad category typically function through two primary mechanisms: non-specific physical shielding or specific molecular blockade. Cytoprotective agents like sucralfate bind non-selectively to positively charged proteins exposed at the base of ulcers, creating a physical barrier against gastric acid and pepsin (Source: DrugBank, DB00364). Conversely, targeted biologics like vedolizumab specifically bind to adhesion molecules (e.g., MAdCAM-1) on mucosal surfaces to inhibit the migration of inflammatory cells into tissues (Source: PubMed, PMID: 24669937).